膀胱尿路上皮细胞癌患者血清CYFRA21-1水平的测定  

Detection of serum CYFRA21-1 in patients with urothelial bladder carcinoma

作　　者：孔朝辉[1] 朱晓博[1] 范小玲[1] 

机构地区：[1]河南省人民医院泌尿外科,郑州450003

出　　处：《郑州大学学报（医学版）》2014年第6期805-807,共3页Journal of Zhengzhou University(Medical Sciences)

基　　金：河南省科技攻关计划项目112102310232

摘　　要：目的:检测膀胱尿路上皮细胞癌患者血清中CYFRA21-1水平并探讨其临床意义。方法:采用电化学发光免疫分析技术检测57例膀胱尿路上皮细胞癌患者和52例泌尿系统良性疾病患者以及49例健康个体血清CYFRA21-1水平。结果:膀胱尿路上皮细胞癌患者血清CYFRA21-1水平和阳性率均高于泌尿系统良性疾病患者与健康人群(F/χ2=28.949、15.221,P均<0.05)。膀胱尿路上皮细胞癌病理分级与血清CYFRA21-1水平及阳性率均无关(P均>0.05)。T3及T3M+期肿瘤较Ta、T1、T2期肿瘤患者血清CYFRA21-1水平及阳性率均升高(F/χ2=2.096、34.232,P均<0.05);与初发肿瘤相比,复发膀胱尿路上皮细胞癌患者血清CYFRA21-1水平及阳性率均升高(t/χ2=3.968、9.541,P均<0.05)。结论:血清CYFRA21-1可以作为膀胱尿路上皮细胞癌的一个可靠的肿瘤标志物,特别是在监测膀胱尿路上皮癌转移或复发时更具优势。Aim：To study value of serum CYFRA21-1 in urothelial bladder carcinoma and its clinical significance . Methods：Electrochemiluminescence method was used to detect serum CYFRA 21-1 level of 158 patients, including 57 ca-ses with urothelial bladder carcinoma （group 1）, 52 cases with benign diseases of the urinary system （group 2）, and 49 healthy individuals（group 3）.Results： Compared with group 2 and group 3, serum CYFRA21-1 level and positive rate were significantly higher in group 1 （F/χ2 =28.949,15.221,P〈0.05）.In group 1, serum CYFRA21-1 levels did not differ significantly among each grade （P〉0.05）.The CYFRA21-1 level and positive rate increased significantly in T 3 and T3M＋stage compared to Ta, T1 and T2 stage（F/χ2 =2.096,34.232,P〈0.05）.Compared with primary tumor, serum CYFRA21-1 level and positive rate were significantly increased in recurrent urothelial bladder carcinoma （ t/χ2 =3.968, 9.541,P〈0.05）.Conclusion：Serum CYFRA21-1 seems to be a marker of urothelial bladder carcinoma .It is useful for monitoring this disease , especially for the metastatic and recurrent tumor .

关 键 词：CYFRA21-1 膀胱尿路上皮细胞癌 

分 类 号：R737.14[医药卫生—肿瘤]